List view / Grid view
28 April 2014 | By Pfizer
This is an announcement of a possible offer falling under Rule 2.4 of the City Code on Takeovers and Mergers (the “Code”)...
25 April 2014 | By Roche
Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older...
25 April 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the discontinuation of the phase 3 clinical trial conducted in Japan for nimotuzumab (DE-766) in Lung Cancer...
25 April 2014 | By Daiichi Sankyo
Kitasato Daiichi Sankyo Vaccine engaged in preparations to build a scheme to supply vaccines by the end of March 2014...
25 April 2014 | By Teva
Study initiation represents significant milestone for patients with a disease with limited effective treatment options...
25 April 2014 | By Novartis
Novartis announced top-line results from the Phase IV INSTEAD switch study in patients with chronic obstructive pulmonary disease, which met its primary objective...
24 April 2014 | By Boehringer Ingelheim
Hydra Biosciences, Inc. and Boehringer Ingelheim jointly announced that they have entered into a worldwide collaboration to research and develop small-molecule TRPC4/5 inhibitors...
24 April 2014 | By Biogen Idec
Quintiles and Biogen Idec have entered into a five-year strategic clinical development agreement...
23 April 2014 | By AbbVie
AbbVie announced that data evaluating a number of investigational compounds in the company's oncology pipeline will be presented at the upcoming 50th Annual Meeting of the American Society of Clinical Oncology...
23 April 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company and Samsung BioLogics announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site...
23 April 2014 | By Pfizer
Pfizer Inc. announced top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079)...
23 April 2014 | By Biogen Idec
Biogen Idec Inc. reported first quarter 2014 results, including revenue of $2.1 billion, a 51% increase compared to the first quarter of 2013...
22 April 2014 | By Enterome
ENTEROME bioscience SA is pleased to announce that Prof. Alessandra Cervino has joined the Company as Head of Discovery...
22 April 2014 | By Novartis
Novartis announced that it has reached a definitive agreement with GlaxoSmithKline plc to exchange certain assets, building global leadership in key segments and focusing the company's portfolio...
22 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announces a major 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses...
